US 11,746,159 B2Granted

Humanized anti-MUC1* antibodies

AssigneeMinerva Biotechnologies Corporation

InventorsCynthia Bamdad, Benoit Smagghe

Life of this patent

Estimating the term…

The present application discloses humanized antibodies and antibody like proteins and fragments thereof.

Dependent claims

A chimeric antigen receptor (CAR) comprising a scFv or humanized scFv of an MN-E6 scFv set forth as consisting of SEQ ID NOS:

233, 235, or 237, MN-C2 scFv set forth as consisting of SEQ ID NOS:239, 241, or 243, MN-C3 scFv set forth as consisting of SEQ ID NOS:
245, 247, or 249 or MN-C8 scFv set forth as consisting of SEQ ID NOS:251, 253, or 255.

Dependencies are inferred from the claim text.

C07K 16/3092
Against structure-related tumour-associated moieties: against tumour-associated mucins
A61K 40/11
Characterised by the cell type used: t-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer…
A61K 40/31
Characterised by the recombinant expression of specific molecules in the cells of the immune system: chimeric antigen receptors [CAR]
A61K 40/32
Characterised by the recombinant expression of specific molecules in the cells of the immune system: t-cell receptors [TCR]

From the US filing history. Foreign family members aren’t listed.

Loading patent…